GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » Enterprise Value

CalciMedica (CalciMedica) Enterprise Value : $22.72 Mil (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CalciMedica Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CalciMedica's Enterprise Value is $22.72 Mil. CalciMedica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-34.25 Mil. Therefore, CalciMedica's EV-to-EBIT ratio for today is -0.66.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, CalciMedica's Enterprise Value is $22.72 Mil. CalciMedica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-34.19 Mil. Therefore, CalciMedica's EV-to-EBITDA ratio for today is -0.66.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, CalciMedica's Enterprise Value is $22.72 Mil. CalciMedica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, CalciMedica's EV-to-Revenue ratio for today is .


CalciMedica Enterprise Value Historical Data

The historical data trend for CalciMedica's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CalciMedica Enterprise Value Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - 513.79 -24.59 76.95 5.22

CalciMedica Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.95 -5.85 3.62 0.53 5.22

Competitive Comparison of CalciMedica's Enterprise Value

For the Biotechnology subindustry, CalciMedica's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CalciMedica's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's Enterprise Value distribution charts can be found below:

* The bar in red indicates where CalciMedica's Enterprise Value falls into.



CalciMedica Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

CalciMedica's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

CalciMedica's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CalciMedica  (NAS:CALC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

CalciMedica's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22.723/-34.247
=-0.66

CalciMedica's current Enterprise Value is $22.72 Mil.
CalciMedica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.25 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

CalciMedica's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=22.723/-34.189
=-0.66

CalciMedica's current Enterprise Value is $22.72 Mil.
CalciMedica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.19 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

CalciMedica's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=22.723/0
=

CalciMedica's current Enterprise Value is $22.72 Mil.
CalciMedica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CalciMedica Enterprise Value Related Terms

Thank you for viewing the detailed overview of CalciMedica's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CalciMedica (CalciMedica) Business Description

Traded in Other Exchanges
N/A
Address
274 Redwood Shores Parkway, P.O. Box 144, Redwood City, CA, USA, 94065
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Executives
Robert N Wilson director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
A. Rachel Leheny director, 10 percent owner, officer: Chief Executive Officer C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Eric W Roberts director, 10 percent owner, officer: Chief Business Officer VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar officer: Chief Medical Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Fred A Middleton director, 10 percent owner 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p. 10 percent owner 1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Co Investment Fund Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn officer: President and COO C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman officer: Chief Scientific Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037

CalciMedica (CalciMedica) Headlines